Market Analysis - Endocrine 2017
The global endocrine testing market has been broadly divided on the basis of diagnostic technologies, selected tests, end-users, and geography. Antidiabetics contributed for 50% of the world endocrine market in 1991, whereas human growth hormones and osteoporosis treatments made up 15% each of the market, while hormone replacement therapy contributed for 10%, according to a data monitor report on the world endocrine market. The largest growth rate is being expected in osteoporosis treatments and hormone replacement therapy, which are both expected to grow by a percent of 24 upto the year 1995. The human growth hormone segment has been forecasted to increase by 18% over the coming three years, and the antidiabetic product market is being estimated to expand by 10% upto the year 1995 on a worldwide basis. The antidiabetic market is the strongest in North America, says a report that accounts for 53% of the total consumption. Europe has 33% of market followed by Japan with 11% and 3% for the rest of the world. The greatest variation comes with the hormone replacement therapy, that of which 71% from North America and 25% from Europe, Japan and rest of the world contributing for only 4%. The osteoporosis treatments are strongest in Europe with 64%, and Japan with 28% and with North America accounting only for 3% of the world market. Human growth hormone distribution is more evenly spread, with Europe contributing 42% to the market, North America with 34%, Japan with 16% and the rest of the world with 8%. As a total market, North America makes 47% of the total endocrine sales, Europe with 38%, Japan with 11% and the rest of the world with 4%.
The global market for endocrinology drugs are divided into diabetes market, growth hormone market, hypogonadism market and acromegaly market. The market for diabetes is experiencing tremendous growth under the influence of rapidly increasing prevalence of diabetes worldwide. According to a report, in 2013, the global population diagnosed with diabetes was 355 million approximately, and is expected to grow to reach 592 million by the end of year 2035. This rapid growth of diabetes fuels is the growth of diabetes market. According to the facts, global prevalence of diabetes has been estimated to be 9% among adults in 2014. Inception of new drug delivery for rising cases of end stage renal disease (ESRD), cancer and growth hormone along with rise in disposable income are the factors that drive the market for human growth hormone. On the other hand off label uses of human growth hormone (HGH) for anti-aging, body building, and in sports are a challenge to the society not only because it is illegal but also due to the use of human growth hormone (HGH) is associated with higher risk and more side effects. Hypogonadism market consists testosterone, progesterone replacement therapy and estrogen market. Such segment will experience a growth due to increasing awareness about the post menopausal hazards among women, awareness about testosterone among men. Extensive R&D is another important factor that propels growth of market. Untill 2013, there are approximately 180 new formulations under the pipeline studies to treat diabetes, out of which, nearly 13 are waiting for approval from regulatory bodies.
According to a report, the global endocrine testing market was valued at around 7.00 billion dollars in 2015 and is expected to reach approximately 10.50 billion dollars by 2021, growing at a CAGR of around 8.5% from 2016 to 2021. Based on the test, the global endocrine testing market has been divided into estradiol (E2), Human Chorionic Gonadotropin (hCG), Follicle Stimulating Hormone (FSH), Luteinizing hormone (LH), progesterone, Dehydroepiandrosterone sulfate (DHEAS), testosterone, Thyroid Stimulating Hormone (TSH), cortisol, prolactin, and insulin tests. The market for these tests is been extensively analyzed based on effectiveness, consistency, and the sales revenue of the various products developed by manufacturers. The market size and forecast in terms of million dollars for each type has been provided for a period between 2013 and 2023. The report on endocrine testing market also provides a compound annual growth rate (CAGR %) for each of the market segments for the forecast period from 2015 to 2023, considering 2014 as a base year.
Geographically, the global endocrine testing market has been segmented into North America, Asia Pacific, Europe and Rest of the World. The market size and forecast for each of the regions have been provided for the period b 2013 to 2023 along with CAGR (%) for the forecast period from 2013 to 2023. The research study also incorporates the competitive scenario of major players in these regions.
North America is currently a leading the sector in the endocrine testing market with the share of over 35.0 percent with respect to the revenue generated in 2015. Key factors such as presence of well-developed healthcare system, rising investment in research and development have contributed to a large share of endocrine testing market in North America. Notably, USA is expected to exhibit considerable growth primarily due to the increasing R&D endeavors. Asia-Pacific is the fastest growing regional market in the coming future. Asia-Pacific is anticipated to overtake Europe, in terms of market share, by 2021 primarily owing to the growing awareness regarding the benefits of digital signage. Endocrine testing market has a huge opportunity in the emerging markets of Asia Pacific region due to increasing rising health awareness about endocrine disorders, aging population and increasing investment in healthcare sector especially in India and China. Europe is anticipated to exhibit significant growth in the upcoming years. The growth is primarily due to increasing concern regarding health amongst the people. Moreover, increasing demand in endocrine testing kits coupled with technological advancement is expected to fuel the market growth within forecast period.
The Middle East & Africa region has been expected to witness significant growth in the coming future. This growth is primarily due to the increase in healthcare awareness with advancement in technology. Latin America is another important regional market and is anticipated to experience noticeable growth during the forecast period. This growth is been mainly attributed to increasing health awareness and favorable government funding. Thus, all the forementioned parameters are expected to propel the market growth in this region.
Conference series welcomes you to the "9th Annual Congress on Endocrine Disorders and Therapies" to be held from September 11-12, 2017 in Dallas, Texas, USA. Endocrine 2017 will provide an opportunity for researchers to interact, share new results, show live demonstrations of their work, and discuss about innovative technologies and applications in many fields, including manufacturing techniques, drug administration techniques, drug discovery, drug delivery, product development etc
Theme of Endocrine 2017
“Collaborative Strategies and Innovative Approaches to fight Endocrine Disorders”